Inter Pharma Public Company Limited (IP-R.BK)
- Previous Close
6.30 - Open
6.25 - Bid 6.15 x --
- Ask 6.20 x --
- Day's Range
6.10 - 6.25 - 52 Week Range
6.10 - 6.25 - Volume
218,000 - Avg. Volume
-- - Market Cap (intraday)
-- - Beta (5Y Monthly) 0.51
- PE Ratio (TTM)
15.38 - EPS (TTM)
0.40 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date May 7, 2024
- 1y Target Est
--
Inter Pharma Public Company Limited manufactures, imports, and distributes dietary supplement products for humans and animals in Thailand. It operates through three: Human Healthcare, Animal Healthcare, and Hospital segments. The company offers human, anti-aging, and human products, such as medical supplies, nutrition therapy, cosmetics, supplementary foods, probiotic and prebiotic products, health food products, general food products, medical equipment and medicines, etc.; functional foods and drinks; and pharmaceutical products; It also provides pet healthcare and livestock products comprising medical supplies, nutrition therapy, vaccines, supplementary foods, probiotic and prebiotic products, animal health food products, premium grade animal foods, general formula animal foods, medical equipment related to pet and livestock care product, etc. In addition, the company provides care and treatment for patients with general and specialized diseases, such as cardiovascular disease, bone and joint disease, neuropathy, medical diseases, surgical diseases, kidney disease, obstetrics and gynecology, ear, eye, nose, throat diseases, blood diseases, pediatric clinics, etc. Further, it offers nutraceuticals, ear and teeth cleaners, pee pads, shampoos, and cosmeceuticals products. The company was incorporated in 2006 and is headquartered in Bangkok, Thailand.
www.interpharma.co.thRecent News: IP-R.BK
Compare To: IP-R.BK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IP-R.BK
Valuation Measures
Market Cap
3.72B
Enterprise Value
3.71B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
2.82%
Return on Assets (ttm)
2.26%
Return on Equity (ttm)
2.78%
Revenue (ttm)
1.8B
Net Income Avi to Common (ttm)
50.79M
Diluted EPS (ttm)
0.40
Balance Sheet and Cash Flow
Total Cash (mrq)
413.25M
Total Debt/Equity (mrq)
18.89%
Levered Free Cash Flow (ttm)
-52.37M
Research Analysis: IP-R.BK
Company Insights: IP-R.BK
IP-R.BK does not have Company Insights